Defence Therapeutics Inc. (CSE:DTC)

Market Cap	35.00M +11.7%
Revenue (ttm)	n/a
Net Income	-3.62M
EPS	-0.07
Shares Out	57.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,119
Average Volume	53,671
Open	0.6000
Previous Close	0.6100
Day's Range	0.6000 - 0.6100
52-Week Range	0.5200 - 1.6600
Beta	1.35
RSI	44.77
Earnings Date	Feb 23, 2026

About Defence Therapeutics

Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; the ARM-X ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: DTC